Milnaneurax (Milnacipran Hydrochloride)

Milnacipran Hydrochloride, the active ingredient in Milnaneurax, is a Serotonin‑Norepinephrine Reuptake Inhibitor (SNRI) presented as an oral tablet for oral use. It is prescribed to treat major depressive disorder and to alleviate the chronic pain associated with fibromyalgia in adult patients.

GNH USA supplies Milnaneurax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milnacipran Hydrochloride is an SNRI indicated for conditions involving mood regulation and chronic pain.

- Major depressive disorder: improves depressive symptoms and functional outcomes in adults. - Fibromyalgia: reduces widespread musculoskeletal pain and enhances daily activity levels.

Milnacipran Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headaches. - Dry mouth: reduced salivation causing discomfort. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Hepatotoxicity: abnormal liver enzymes indicating possible liver injury. - Serotonin syndrome: signs of excessive serotonergic activity such as agitation, hyperthermia, and tremor. - Suicidal ideation: emergence of thoughts of self‑harm, especially early in treatment.

Before initiating therapy with Milnacipran Hydrochloride, certain precautions should be observed.

- Cardiovascular assessment: evaluate blood pressure and heart rate regularly. - Hepatic function: monitor liver enzymes in patients with liver disease. - Psychiatric monitoring: watch for worsening depression or emergence of suicidal thoughts. - Drug discontinuation: taper gradually to avoid withdrawal symptoms. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Milnacipran Hydrochloride can interact with several other medicines, influencing safety and efficacy.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Tricyclic antidepressants: additive hypertensive effects. - CYP2D6 inhibitors (e.g., fluoxetine): increased milnacipran plasma levels.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, tramadol): monitor for serotonin syndrome. - Antihypertensive drugs: possible attenuation of blood‑pressure‑lowering effect. - NSAIDs: heightened risk of gastrointestinal bleeding.